General Anesthesia/Surgical Exposure on White Matter Development in Children
A Study of the Effects of General Anesthesia/Surgical Exposure on Distant Cerebral White Matter Development in Children
1 other identifier
observational
210
0 countries
N/A
Brief Summary
International large-scale clinical studies have found that prolonged or repeated exposure to general anesthesia drugs in infancy and early childhood can lead to an increased risk of long-term neurodevelopmental abnormalities in children. The study of neurodevelopmental toxicity of general anesthesia drugs is of great social significance. We have established a rhesus monkey model to study the neurodevelopmental toxicity of general anesthetic drugs, the first time to make a preliminary exploration of the mechanism of myelin developmental toxicity of general anesthetic drugs. Several studies using magnetic resonance scanning found a positive correlation between the number of anesthesia exposures and the maturity of distant brain white matter development in juvenile non-human primates. Clinical evidence for myelin developmental toxicity induced by general anesthetic drugs needs to be collected by conducting multicenter and large-sample clinical studies. Earlier studies have either had low sample sizes, which do not allow for better control of confounding factors; or the study population has been limited to specific disease populations, and the results cannot be extrapolated to normal children. In view of this, based on the applicant's earlier study, this project proposes to recruit children who underwent general anesthesia surgery between 0-3 years of age and are now 12-15 years old; children who did not experience surgery between 0-3 years of age were matched by age-sex to serve as a control group. MRI will be used to assess their brain white matter development, to explore the correlation between anesthesia and anesthesia-related factors and brain white matter development and related neurobehavioral development, and to clarify the effects of anesthesia and surgery on children's brain white matter and related neuropsychological development.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2024
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 10, 2024
CompletedFirst Posted
Study publicly available on registry
April 16, 2024
CompletedStudy Start
First participant enrolled
May 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
April 16, 2024
December 1, 2023
2.6 years
April 10, 2024
April 15, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
MRI-based assessment of brain development
Magnetic resonance scanning of T1-weighted images, T2-weighted images, and diffusion tensor imaging (DTI) of both cerebral hemispheres, looking at whole-brain white matter volume as a percentage of total intracranial volume
one time, through study completion, an average of 3 month
Study Arms (3)
Multiple anesthesia group
Children who underwent more than one general anesthesia procedure between the ages of 0-3 years.
Single anesthesia group
Children who underwent only one general anesthesia procedure between the ages of 0-3 years.
Control group
Children who underwent no general anesthesia procedure between the ages of 0-3 years.
Interventions
MRI is used to assess of brain development.
Eligibility Criteria
Age between 12-15 years.Past history doesn't lead to abnormal brain development.
You may qualify if:
- Currently between 12 and 15 years of age
You may not qualify if:
- Surgical complications such as acute infectious diseases, systemic diseases
- Abnormal findings on cerebral white matter and/or neurobehavioral assessment
- History of neonatal ischemic-hypoxic encephalopathy, bilirubin encephalopathy
- Genetic or chromosomal disorders, neurological disorders (including epilepsy, congenital disorders), or a history of craniocerebral trauma, infectious diseases of the central nervous system, febrile convulsions, congenital heart disease, oncological diseases, and blood disorders
- Autism, attention deficit hyperactivity disorder, or those who have received behavioral therapy and intervention.
- Children with organic damage to the nervous system
- Cardiovascular surgery, neurosurgery or intraoperative hemodynamic instability.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 10, 2024
First Posted
April 16, 2024
Study Start
May 1, 2024
Primary Completion (Estimated)
November 30, 2026
Study Completion (Estimated)
December 31, 2026
Last Updated
April 16, 2024
Record last verified: 2023-12